CA2651033A1 - Constrained compounds as cgrp-receptor antagonists - Google Patents

Constrained compounds as cgrp-receptor antagonists Download PDF

Info

Publication number
CA2651033A1
CA2651033A1 CA002651033A CA2651033A CA2651033A1 CA 2651033 A1 CA2651033 A1 CA 2651033A1 CA 002651033 A CA002651033 A CA 002651033A CA 2651033 A CA2651033 A CA 2651033A CA 2651033 A1 CA2651033 A1 CA 2651033A1
Authority
CA
Canada
Prior art keywords
oxo
mmol
mixture
indazol
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002651033A
Other languages
English (en)
French (fr)
Inventor
Prasad V. Chaturvedula
Stephen E. Mercer
Haiquan Fang
Xiaojun Han
Guanglin Luo
Gene M. Dubowchik
Graham S. Poindexter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2651033A1 publication Critical patent/CA2651033A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA002651033A 2006-05-03 2007-05-02 Constrained compounds as cgrp-receptor antagonists Abandoned CA2651033A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US79740006P 2006-05-03 2006-05-03
US60/797,400 2006-05-03
US11/742,626 US7470680B2 (en) 2006-05-03 2007-05-01 Constrained compounds as CGRP-receptor antagonists
US11/742,626 2007-05-01
PCT/US2007/067998 WO2007131020A2 (en) 2006-05-03 2007-05-02 Constrained compounds as cgrp-receptor antagonists

Publications (1)

Publication Number Publication Date
CA2651033A1 true CA2651033A1 (en) 2007-11-15

Family

ID=38544174

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002651033A Abandoned CA2651033A1 (en) 2006-05-03 2007-05-02 Constrained compounds as cgrp-receptor antagonists

Country Status (14)

Country Link
US (1) US7470680B2 (enExample)
EP (1) EP2013214B1 (enExample)
JP (1) JP2009535429A (enExample)
KR (1) KR20090018930A (enExample)
AR (1) AR060845A1 (enExample)
AU (1) AU2007248038A1 (enExample)
BR (1) BRPI0709759A2 (enExample)
CA (1) CA2651033A1 (enExample)
IL (1) IL195027A0 (enExample)
MX (1) MX2008013760A (enExample)
NO (1) NO20084564L (enExample)
PE (1) PE20080232A1 (enExample)
TW (1) TW200813063A (enExample)
WO (1) WO2007131020A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384931B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
JP2010513489A (ja) * 2006-12-20 2010-04-30 メルク・シャープ・エンド・ドーム・コーポレイション Cgrp受容体アンタゴニストであるベンゾアゼピン化合物
WO2009105348A1 (en) * 2008-02-19 2009-08-27 Merck & Co., Inc. Imidazobenzazepine cgrp receptor antagonists
US8685969B2 (en) 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
WO2024220626A1 (en) * 2023-04-20 2024-10-24 Azkarra Therapeutics, Inc. Small molecule modulators of ogg1

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004222378B2 (en) 2003-03-14 2008-08-14 Merck Sharp & Dohme Corp. Carboxamide spirohydantoin CGRP receptor antagonists
US7205293B2 (en) 2003-03-14 2007-04-17 Merck & Co., Inc. Benodiazepine spirohydantoin CGRP receptor antagonists
WO2004091514A2 (en) 2003-04-15 2004-10-28 Merck & Co., Inc. Cgrp receptor antagonists
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
WO2005013894A2 (en) 2003-06-26 2005-02-17 Merck & Co., Inc. Benzodiazepine cgrp receptor antagonists
AU2004252150B2 (en) 2003-06-26 2008-11-20 Merck Sharp & Dohme Corp. Benzodiazepine CGRP receptor antagonists
WO2005072308A2 (en) 2004-01-29 2005-08-11 Merck & Co., Inc. Cgrp receptor antagonists
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
WO2006041830A2 (en) 2004-10-07 2006-04-20 Merck & Co., Inc. Cgrp receptor antagonists
BRPI0517418A (pt) 2004-10-13 2008-10-07 Merck & Co Inc composto, composição farmacêutica, e, métodos para antagonismo de atividade do receptor de cgrp em um mamìfero, para tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca ou cefalgia, e de tratamento ou prevenção de dores de cabeça de enxaqueca, cefalgias, e dores de cabeça
CN101039718A (zh) 2004-10-14 2007-09-19 默克公司 Cgrp受体拮抗剂
US7745427B2 (en) 2004-10-22 2010-06-29 Merck Sharp & Dohme Corp. CGRP receptor antagonists
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
ATE466853T1 (de) 2005-01-18 2010-05-15 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
CA2599925A1 (en) 2005-03-14 2006-09-21 Merck & Co., Inc. Cgrp receptor antagonists
CA2615463A1 (en) 2005-07-29 2007-02-08 Merck & Co., Inc. Heterocyclic benzodiazepine cgrp receptor antagonists
JP2010513489A (ja) 2006-12-20 2010-04-30 メルク・シャープ・エンド・ドーム・コーポレイション Cgrp受容体アンタゴニストであるベンゾアゼピン化合物

Also Published As

Publication number Publication date
WO2007131020A3 (en) 2008-01-17
TW200813063A (en) 2008-03-16
BRPI0709759A2 (pt) 2011-10-25
AR060845A1 (es) 2008-07-16
JP2009535429A (ja) 2009-10-01
MX2008013760A (es) 2008-11-14
WO2007131020A2 (en) 2007-11-15
AU2007248038A1 (en) 2007-11-15
KR20090018930A (ko) 2009-02-24
EP2013214A2 (en) 2009-01-14
PE20080232A1 (es) 2008-04-11
NO20084564L (no) 2008-12-02
EP2013214B1 (en) 2015-06-24
US7470680B2 (en) 2008-12-30
US20070259851A1 (en) 2007-11-08
IL195027A0 (en) 2009-08-03

Similar Documents

Publication Publication Date Title
US7544680B2 (en) Constrained compounds as CGRP-receptor antagonists
AU2019294482B2 (en) Heteroaryl compounds for treating Huntington's disease
KR20250024833A (ko) 테트라하이드로피리도피리미딘 PAN-Kras 억제제
EP1945222B1 (en) Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
AU2010306954B2 (en) CGRP receptor antagonists
ES2392779T3 (es) Derivados de piperidina como antagonistas del receptor de CGRP
WO2007130860A2 (en) Constrained compounds as cgrp-receptor antagonists
EP2013214B1 (en) Constrained compounds as cgrp-receptor antagonists
CN121568945A (zh) 用于治疗自身免疫病的大环
TW202345797A (zh) 作為ikzf2降解劑之含雙環雜芳基化合物
EP2013213B1 (en) Constrained compounds as cgrp-receptor antagonists
CN101495480B (zh) 作为降钙素基因相关肽受体拮抗剂的受限化合物
WO2020011921A1 (en) P2x3 receptor antagonists
AU2006245517A1 (en) Quinoline derivatives as neurokinin receptor antagonists
CN121949345A (zh) 杂芳基大环化合物及其制备方法和应用

Legal Events

Date Code Title Description
FZDE Discontinued